It is concluded that EAM-2201 has the probable to trigger in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and is evaluated in pooled human liver microsomes. In vitro final results indicate that AM-2201 needs to be examined for possible pharmacokinetic drug interactions in vivo https://am220109752.governor-wiki.com/1066475/the_5_second_trick_for_eam2201